Tag
An updated meta-analysis suggests lymph node dissection in intrahepatic cholangiocarcinoma may improve survival when it is truly adequate, especially when at least six nodes are retrieved and confounding is reduced.
The Phase 2 ACC trial demonstrates that adjuvant camrelizumab combined with capecitabine achieves a median recurrence-free survival of 24.29 months for patients with resected intrahepatic cholangiocarcinoma, offering a promising and managea
The PUMP‑2 phase II trial reports that hepatic arterial infusion (HAIP) of floxuridine combined with systemic gemcitabine–cisplatin achieved a 1‑year overall survival of 80% and median OS of 22.3 months in unresectable liver‑confined intrah
Pooled Phase I/IIa data (n=24) indicate intratumoural VG161 is well tolerated in advanced intrahepatic cholangiocarcinoma, elicits local and systemic immune activation (APC recruitment, CD8+ T‑cell activation, M2 macrophage depletion) and s
Xanthine oxidoreductase (XOR) drives resistance to EGFR tyrosine kinase inhibitors in intrahepatic cholangiocarcinoma by stabilizing EGFR and enhancing DNA repair. Targeting XOR sensitizes tumors to EGFR TKIs and suppresses cancer progressi
This article reviews the immunosuppressive mechanisms of tumour-infiltrating B cells in intrahepatic cholangiocarcinoma (iCCA), their impact on prognosis, and potential to enhance chemoimmunotherapy efficacy by restoring B-cell function and
This observational study reveals stable global biliary tract cancer mortality rates over two decades, with a striking rise in intrahepatic cholangiocarcinoma mortality, underscoring the need for targeted screening and management strategies.
A nationwide Swedish study reveals significant socioeconomic disparities in intrahepatic cholangiocarcinoma incidence, treatment access, and survival despite universal healthcare coverage, underscoring persistent health inequities linked to
